These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18565458)

  • 41. A series of 7 cases of patients with narcolepsy with hypocretin deficiency without the HLA DQB1*06:02 allele.
    Miano S; Barateau L; De Pieri M; Riccardi S; Thevenin C; Manconi M; Dauvilliers Y
    J Clin Sleep Med; 2023 Dec; 19(12):2053-2057. PubMed ID: 37539640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality.
    Ruoff C; Rye D
    Curr Med Res Opin; 2016 Oct; 32(10):1611-1622. PubMed ID: 27359185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
    Nishino S; Ripley B; Overeem S; Nevsimalova S; Lammers GJ; Vankova J; Okun M; Rogers W; Brooks S; Mignot E
    Ann Neurol; 2001 Sep; 50(3):381-8. PubMed ID: 11558795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CSF orexin-A/hypocretin-1 concentrations in patients with intracerebral hemorrhage (ICH).
    Dohi K; Ripley B; Fujiki N; Ohtaki H; Yamamoto T; Goto Y; Nakamachi T; Shioda S; Aruga T; Nishino S
    Regul Pept; 2008 Jan; 145(1-3):60-4. PubMed ID: 17868933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1.
    van der Hoeven AE; Fronczek R; Schinkelshoek MS; Roelandse FWC; Bakker JA; Overeem S; Bijlenga D; Lammers GJ
    Sleep; 2022 May; 45(5):. PubMed ID: 35554594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.
    Nishino S; Sakurai E; Nevsimalova S; Yoshida Y; Watanabe T; Yanai K; Mignot E
    Sleep; 2009 Feb; 32(2):175-80. PubMed ID: 19238804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy.
    Martinez-Rodriguez JE; Seppi K; Cardozo A; Iranzo A; Stampfer-Kountchev M; Wenning G; Tolosa E; Högl B; Santamaria J; Poewe W;
    Mov Disord; 2007 Sep; 22(12):1822-4. PubMed ID: 17659646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The hypothalamic peptidergic system, hypocretin/orexin and vigilance control.
    Nishino S
    Neuropeptides; 2007 Jun; 41(3):117-33. PubMed ID: 17376528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Normal cerebrospinal fluid levels of hypocretin-1 (orexin A) in patients with fibromyalgia syndrome.
    Taiwo OB; Russell IJ; Mignot E; Lin L; Michalek JE; Haynes W; Xiao Y; Zeitzer JM; Larson AA
    Sleep Med; 2007 Apr; 8(3):260-5. PubMed ID: 17369087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypocretin deficiency in Prader-Willi syndrome.
    Nevsimalova S; Vankova J; Stepanova I; Seemanova E; Mignot E; Nishino S
    Eur J Neurol; 2005 Jan; 12(1):70-2. PubMed ID: 15613151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis.
    Van Rooij FG; Schelhaas HJ; Lammers GJ; Verbeek MM; Overeem S
    Amyotroph Lateral Scler; 2009; 10(5-6):487-9. PubMed ID: 19922146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy.
    Savvidou A; Knudsen S; Olsson-Engman M; Gammeltoft S; Jennum P; Palm L
    Sleep; 2013 Jan; 36(1):147-8. PubMed ID: 23288981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melanin concentrating hormone in central hypersomnia.
    Peyron C; Valentin F; Bayard S; Hanriot L; Bedetti C; Rousset B; Luppi PH; Dauvilliers Y
    Sleep Med; 2011 Sep; 12(8):768-72. PubMed ID: 21697009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Narcolepsy: a review of evidence for autoimmune diathesis.
    Black JL
    Int Rev Psychiatry; 2005 Dec; 17(6):461-9. PubMed ID: 16401544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypocretin/orexin disturbances in neurological disorders.
    Fronczek R; Baumann CR; Lammers GJ; Bassetti CL; Overeem S
    Sleep Med Rev; 2009 Feb; 13(1):9-22. PubMed ID: 18819824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.
    Baumann CR; Dauvilliers Y; Mignot E; Bassetti CL
    Eur Neurol; 2004; 52(2):73-6. PubMed ID: 15256827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders.
    Arii J; Kanbayashi T; Tanabe Y; Sawaishi Y; Kimura S; Watanabe A; Mishima K; Hishikawa Y; Shimizu T; Nishino S
    Neurology; 2004 Dec; 63(12):2440-2. PubMed ID: 15623725
    [No Abstract]   [Full Text] [Related]  

  • 58. Narcolepsy in Parkinson's disease.
    Haq IZ; Naidu Y; Reddy P; Chaudhuri KR
    Expert Rev Neurother; 2010 Jun; 10(6):879-84. PubMed ID: 20518604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hypocretin system and narcolepsy].
    Arias-Carrión O
    Rev Med Chil; 2009 Sep; 137(9):1209-16. PubMed ID: 20011964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Hypocretin disturbance and sleep disorders].
    Billiard M
    Bull Acad Natl Med; 2011 Oct; 195(7):1567-78; discussion 1579-81. PubMed ID: 22812161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.